IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases... Show more
IN8bio is a clinical-stage biotechnology company developing gamma-delta (γδ) T cell therapies and T cell engagers (TCEs), an emerging class of immune-based treatments targeting cancer and autoimmune diseases. Because the company is still in the development stage, it generates no product revenue, so investors focus almost entirely on two things: the pace of clinical and preclinical progress, and the durability of its cash balance. With lead programs such as INB-100 in high-risk leukemias and the INB-600 engager platform still early in development, each quarterly report serves as a checkpoint on both scientific momentum and how long the company can fund operations before needing additional capital.
For the three months ended September 30, 2026, IN8bio reported a net loss of $4.6 million, or $0.24 per basic and diluted share, versus a net loss of $3.9 million, or $0.85 per share, in the prior-year period. While the per-share figure beat the consensus estimate of approximately $0.34, the improvement was driven by a larger weighted-average share count rather than a smaller total loss, which actually widened year over year.
R&D expenses rose to $2.6 million from $2.1 million a year earlier, reflecting higher preclinical costs tied to the T cell engager platform. G&A expenses increased to $2.1 million from $1.9 million, primarily due to higher spending on professional services. The company generated no revenue during the quarter. As of September 30, 2026, cash stood at approximately $14.0 million, compared with $10.7 million a year earlier but down from $27.1 million at the close of 2025.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like IN8bio alongside the broader biotechnology sector, the AI Screener offers a practical way to narrow the field and monitor developing setups.
IN8bio shares fell roughly 10.8% on the day results were reported, closing near $0.83. The decline underscores a familiar dynamic for pre-revenue biotechs: an earnings-per-share (EPS) "beat" carries limited weight when it stems from share dilution and is accompanied by a thinning cash position and a going-concern warning. Investor sentiment remains focused on the company's funding runway and the timing of upcoming data readouts rather than on quarterly loss figures. With a modest market capitalization and limited analyst coverage, trading can be volatile around both earnings and clinical announcements, and the latest report did little to ease concerns about near-term capital needs.
The most important near-term question for IN8bio is financing. With cash of about $14.0 million at the end of September and management flagging substantial doubt about its ability to continue as a going concern, investors will be watching closely for any capital-raising activity and the potential dilution that could accompany it. The company's path forward depends on extending its cash runway while advancing its pipeline.
On the scientific side, attention remains on the INB-600 T cell engager platform, where initial in vivo (animal) data is expected around the end of 2026. Positive results could validate the platform's potential across oncology and autoimmune indications and reshape sentiment. Progress updates on INB-100, an allogeneic gamma-delta T cell therapy for high-risk leukemias, and the INB-200/400 program in glioblastoma will also matter for the longer-term story.
Cost trends are another area to monitor. R&D spending is rising as preclinical work on the engager platform intensifies, which could keep the quarterly loss elevated even as per-share figures fluctuate with share counts. For now, the investment case hinges less on any single quarter's numbers and more on the combination of clinical data catalysts, disciplined spending, and the company's ability to secure additional funding without excessive dilution.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry Biotechnology